NEW YORK (GenomeWeb News) — Indiana-based start-up Kylin Pharmaceuticals has licensed the rights to use more than 12 RNAi-related patents from the Purdue Research Foundation to develop drugs, the Foundation said today.
 
Kylin has received start-up capital from the Indiana venture group IN-vivo Ventures, and from the Research Triangle Park, NC-based Golden Pine Ventures. The company initially plans to focus its efforts on developing therapeutics for cancer, and for viral diseases such as AIDS later.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.